Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 8:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 2,506 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Normal Subjects Clear all
Recruiting No phase listed Observational Accepts healthy volunteers

Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies

NCT00451022
View directory record Official record
Conditions
Prostate Cancer, Liver Cancer, Breast Cancer, Colon Cancer, Lung Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 29, 2026, 8:41 PM EDT
Completed Phase 2 Interventional

Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis

NCT01384630
View directory record Official record
Conditions
Psoriasis
Interventions
RA-18C3
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
Owensboro, Kentucky • Ann Arbor, Michigan • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 29, 2026, 8:41 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants

NCT03451851
View directory record Official record
Conditions
Psoriasis
Interventions
Guselkumab, Placebo for guselkumab, Etanercept
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
6 Years to 17 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
10
States / cities
Palo Alto, California • San Diego, California • Macon, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 29, 2026, 8:41 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Double-blind, Vehicle-controlled Study of the Efficacy and Safety of SADBE in Subjects With Recurrent Herpes Labialis

NCT02965781
View directory record Official record
Conditions
Herpes Labialis, Cold Sore
Interventions
SADBE, Placebo
Drug · Other
Lead sponsor
Squarex, LLC
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
5
States / cities
Redwood City, California • Doral, Florida • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 29, 2026, 8:41 PM EDT
Completed Phase 2 Interventional

Active-Controlled Study to Assess the Efficacy and Safety of DFD-05 in Subjects With Common Warts

NCT02798419
View directory record Official record
Conditions
Common Warts
Interventions
DFD05 Cream, Active01 Cream
Drug
Lead sponsor
Dr. Reddys Laboratories, SA
Industry
Eligibility
18 Years to 50 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
12
States / cities
Hot Springs, Arkansas • Fremont, California • Sacramento, California + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2016 · Synced Oct 29, 2026, 8:41 PM EDT
Recruiting Not applicable Interventional

Trial to Evaluate the Safety and Effectiveness of Treatment With COMS One Device in Subjects With Diabetic Foot Ulcers

NCT05758545
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
COMS One device, Sham device
Device
Lead sponsor
Piomic Medical
Industry
Eligibility
22 Years to 90 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
30
States / cities
Mesa, Arizona • Tucson, Arizona • Castro Valley, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 29, 2026, 8:41 PM EDT
Completed Phase 3 Interventional Results available

Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy

NCT02886728
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Filgotinib, Placebo to match filgotinib, MTX, Placebo to match MTX
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
1,252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
45
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2021 · Synced Oct 29, 2026, 8:41 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of a Novel Malathion Formulation in the Treatment of Head Lice

NCT00244439
View directory record Official record
Conditions
Lice Infestations
Interventions
MALG, Ovide (malathion) lotion 0.05%, Permethrin 1%
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
2 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
6
States / cities
Scottsdale, Arizona • Miami, Florida • St. Petersburg, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2013 · Synced Oct 29, 2026, 8:41 PM EDT
Completed Phase 3 Interventional Results available

Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement

NCT04713592
View directory record Official record
Conditions
Psoriasis
Interventions
Placebo for Risankizumab, Risankizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
34
States / cities
Glendale, Arizona • Hot Springs, Arkansas • Rogers, Arkansas + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2024 · Synced Oct 29, 2026, 8:41 PM EDT
Terminated Phase 1 Interventional

A Study of PLX73086 in Advanced Solid Tumors and Locally Advanced or Refractory Tenosynovial Giant Cell Tumor

NCT02673736
View directory record Official record
Conditions
Solid Tumors, Tenosynovial Giant Cell Tumor, Synovitis, Pigmented Villonodular
Interventions
PLX73086
Drug
Lead sponsor
Plexxikon
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Scottsdale, Arizona • Detroit, Michigan • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2018 · Synced Oct 29, 2026, 8:41 PM EDT
Completed Phase 1 Interventional

Phase 1 Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)

NCT00657007
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
belimumab, Placebo
Biological
Lead sponsor
Human Genome Sciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2013 · Synced Oct 29, 2026, 8:41 PM EDT
Completed Phase 4 Interventional Results available

Moderate Rheumatoid Arthritis (RA) With Etanercept (Enbrel)

NCT01313208
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
etanercept, Placebo, DMARD Therapy
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
38
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Peoria, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Oct 29, 2026, 8:41 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of AMG 557 in Subjects With Systemic Lupus Erythematosus

NCT02391259
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
AMG 557, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 70 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
12
States / cities
Anniston, Alabama • Phoenix, Arizona • Los Angeles, California + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2015 · Synced Oct 29, 2026, 8:41 PM EDT
Completed Phase 1 Interventional

A Phase I Topotecan Study in Subjects With Cancer and Impaired Renal Function

NCT00483860
View directory record Official record
Conditions
Solid Tumours
Interventions
Topotecan
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
2
States / cities
Scottsdale, Arizona • Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 29, 2026, 8:41 PM EDT
Completed Phase 2 Interventional Results available

Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis

NCT06144424
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Oral EP262, Placebo
Drug
Lead sponsor
Escient Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
9
States / cities
Birmingham, Alabama • Miami Lakes, Florida • Plainfield, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2025 · Synced Oct 29, 2026, 8:41 PM EDT
Completed Phase 2 Interventional

A Study to Determine the Safety and Tolerability of 2 Concentrations of QLS-101

NCT04947124
View directory record Official record
Conditions
Sturge-Weber Syndrome (SWS), Glaucoma, Glaucoma Congenital, Ocular Hypertension
Interventions
QLS-101ophthalmic solution 1%, QLS-101ophthalmic solution 2%
Drug
Lead sponsor
Qlaris Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 20, 2025 · Synced Oct 29, 2026, 8:41 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate of the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Acneiform Rash

NCT04697069
View directory record Official record
Conditions
Acneiform Eruptions
Interventions
Imsidolimab, Placebo
Biological
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
5
States / cities
Tampa, Florida • Boston, Massachusetts • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Oct 29, 2026, 8:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics of AT1001 (Migalastat HCl) in Healthy Subjects and Subjects With Impaired Renal Function

NCT01730469
View directory record Official record
Conditions
Fabry Disease
Interventions
AT1001 150 mg
Drug
Lead sponsor
Amicus Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
4
States / cities
Costa Mesa, California • Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 3, 2017 · Synced Oct 29, 2026, 8:41 PM EDT
Completed Phase 3 Interventional Results available

A Study of Ustekinumab to Evaluate a "Subject-tailored" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis

NCT01550744
View directory record Official record
Conditions
Psoriasis
Interventions
Ustekinumab 45 mg, Ustekinumab 90 mg, Placebo
Drug
Lead sponsor
Janssen Biotech, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
40
States / cities
Birmingham, Alabama • Bakersfield, California • Irvine, California + 37 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Oct 29, 2026, 8:41 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.

NCT00116844
View directory record Official record
Conditions
Infections, Herpesviridae
Interventions
Valaciclovir, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
17
States / cities
Carmichael, California • Davis, California • Riverside, California + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2018 · Synced Oct 29, 2026, 8:41 PM EDT
Recruiting Phase 3 Interventional

Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)

NCT07637734
View directory record Official record
Conditions
Common Warts, Common Warts (Verruca Vulgaris), Human Papilloma Virus (HPV), Warts
Interventions
VP-102 (US) / TO-208 (Japan), Vehicle (US) / Vehicle (Japan)
Combination Product
Lead sponsor
Verrica Pharmaceuticals Inc.
Industry
Eligibility
2 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
12
States / cities
San Diego, California • Jacksonville, Florida • Sweetwater, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 29, 2026, 8:41 PM EDT
Completed Phase 3 Interventional Results available

A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or Scalp

NCT03285477
View directory record Official record
Conditions
Actinic Keratoses
Interventions
Placebo, KX2-391 Ointment 1%
Drug
Lead sponsor
Almirall, S.A.
Industry
Eligibility
18 Years and older
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
30
States / cities
Mobile, Alabama • Glendale, Arizona • Fremont, California + 27 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Oct 29, 2026, 8:41 PM EDT
Completed Phase 2 Interventional Results available

Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).

NCT04068181
View directory record Official record
Conditions
Melanoma
Interventions
Talimogene laherparepvec, Pembrolizumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
10
States / cities
Santa Barbara, California • Newark, Delaware • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Oct 29, 2026, 8:41 PM EDT
Completed Phase 2 Interventional

Treating Rheumatoid Arthritis With Tripterygium Wilfordi Hook F or Sulfasalazine

NCT00062465
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
TwHF
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
Not listed
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 29, 2026, 8:41 PM EDT